Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

3rd Annual Stability Testing Conference

Next-Gen Sequencing Trends 2009

Competitor Analysis: c-MET/HGF Inhibitors

The Japanese Pharmaceutical Market 2008-2023

New Products

Japanese Pharmaceutical Market 2009-2024

3rd Annual Lyophilisation Conference

The Global Bioinformatics Market: Market size, forecasts and company profiles

Pharmaceutical Mergers and Acquisitions (PH133)

Pharmaceutical Speaker Programs (PH134) Measuring ROI and Communicating Value

Strategic Clinical Sourcing (PH125)) Managing Costs and CROs

The Global Analgesics Market 2009-2024

Competitor Analysis: Coagulation Factors

Competitor Analysis: PDGF-R Agonists and Antagonists

World Market for Addiction Disorders, 2009-2016

BioPortfolio | Kalorama Reports | Stem Cells Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development

Stem Cells Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development

With their ability to differentiate and become an ongoing source of cells that make up critical tissues and organs, stem cells have potential for new regenerative therapies and as new research tools for drug developers to test emerging therapies on diseased cells.

For market-watchers in the pharmaceutical industry, the question is what potential they have and where they could take the market. Kalorama Information has tackled that question in Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development. Kalorama analyst Alison Sahoo has built models to determine the best, moderate and worst case scenarios for the three key markets for stem cells:

* Stem Cell Therapeutics (Transplantation)

* Cord Blood Banking and

* Drug development

This report breaks down forecasted revenues and procedure volumes for stem cell technologies for these segments in the following disease areas:

* Cardiovascular disease

* Lung disease

* Arthritis

* Incontinence

* Osteoporosis

* Diabetes

* Cancer

* Orthopedics

* Infertility

* Alzheimer’s disease

* Burns (severe)

* Lupus

* Parkinson’s disease

* Liver failure

* Multiple sclerosis

* Critical limb ischemia

* Crohn's disease

* Sickle cell disease

* Multiple myeloma

* NH lymphoma

* Leukemia

Ths report is the result of exclusive interviews with executives in the stem cell industry, a review of medical and company literature, government databases and publications. As part of this comprehensive analysis of stem cell markets, the following companies were profiled:

* Aastrom Biosciences

* Advanced Cell Technologies

* Brainstorm Cell Therapeutics

* Celegene

* Cord Blood America

* Cord Blood Registry

* Cryo-Cell International

* ES Cell International

* Geron

* Harvest Technologies

* Invitrogen

* Medistem

* Neostem

* Opexa Therapeutics

* Osiris Therapeutics

* Plureon

* Regenetech

* Revivicor

* Stem Cell Sciences

* StemLifeLine

* ThermoGenesis

* VetCell Bioscience

* ViaCell

Mar 1, 2008 250 Pages
Table of Contents
Price: $3,995.00 / €2,672.66

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions